At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 520 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study
In Brief
A Phase 3 clinical trial evaluating Galcanezumab and Placebo for Episodic Migraine. Completed, enrolled 520 participants across 40 sites in 3 countries.
Detailed Summary
The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisodic Migraine
CountriesChina, India, Russia
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJul 2019
Primary CompletionJul 2021
Study CompletionMar 2022
TodayJul 2026
First PostedMay 24, 2019
Enrollment StartJul 30, 2019
Primary CompletionJul 27, 2021
Study CompletionMar 11, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.1 years ago
Interventions
Galcanezumabdrug
Administered SC
Placebodrug
Administered SC